Cargando…

SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series

BACKGROUND: Despite the promising results for treating metastatic cancer with checkpoint inhibitor immunotherapies, there are limited data on surgical outcomes for brain metastases (BMs) that have progressed after prior checkpoint inhibitor treatment. The objective of this study was to identify fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Morshed, Ramin, Chung, Jason, Sudhakar, Vivek, Cummins, Daniel, Young, Jacob, Hervey-Jumper, Shawn, Theodosopoulos, Philip, Aghi, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351241/
http://dx.doi.org/10.1093/noajnl/vdab071.104
_version_ 1783735931634712576
author Morshed, Ramin
Chung, Jason
Sudhakar, Vivek
Cummins, Daniel
Young, Jacob
Hervey-Jumper, Shawn
Theodosopoulos, Philip
Aghi, Manish
author_facet Morshed, Ramin
Chung, Jason
Sudhakar, Vivek
Cummins, Daniel
Young, Jacob
Hervey-Jumper, Shawn
Theodosopoulos, Philip
Aghi, Manish
author_sort Morshed, Ramin
collection PubMed
description BACKGROUND: Despite the promising results for treating metastatic cancer with checkpoint inhibitor immunotherapies, there are limited data on surgical outcomes for brain metastases (BMs) that have progressed after prior checkpoint inhibitor treatment. The objective of this study was to identify factors associated with local progression, leptomeningeal disease, and survival for patients undergoing surgical resection of a BM in patients previously treated with checkpoint inhibitor immunotherapy. METHODS: A retrospective, single-center cohort study was conducted with inclusion of adult patients undergoing surgical resection of a BM in the setting of progression after prior checkpoint inhibitor treatment. Univariate and multivariate analyses were performed to identify factors associated with outcomes of interest. RESULTS: Over an 8-year period, 26 patients who underwent resection of 30 BMs met inclusion criteria. Median patient age at surgery was 63.9 years, and median clinical follow-up was 6.9 months (range 0.1 – 52.9). Extracranial disease was present at the time of surgery in 73.3% of cases. There were 6 postoperative complication events (20% of cases) by 30-days. By last follow-up, 65.4% of the cohort had died with a median censored survival of 7.6 months from surgery. Eight patients (30.8%) died within 3 months of surgery. On multivariate analysis, postoperative complications were associated with worse survival (HR 5.33, 95%CI 1.15–24.77, p=0.03). Four BMs had local progression (13.3%), and 60% of procedures were associated with distant progression within a median time of 3.6 months. Leptomeningeal disease developed in 32% of cases. On multivariate analysis, increased time from BM diagnosis to surgery was associated with a greater risk of leptomeningeal disease (OR 1.2, 95%CI 1.00–1.43, p=0.021). CONCLUSION: Patients who require BM resection after prior checkpoint inhibitor treatment have an overall poor prognosis. Although local control rates are acceptable, these patients are at high risk for developing leptomeningeal disease postoperatively.
format Online
Article
Text
id pubmed-8351241
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83512412021-08-09 SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series Morshed, Ramin Chung, Jason Sudhakar, Vivek Cummins, Daniel Young, Jacob Hervey-Jumper, Shawn Theodosopoulos, Philip Aghi, Manish Neurooncol Adv Supplement Abstracts BACKGROUND: Despite the promising results for treating metastatic cancer with checkpoint inhibitor immunotherapies, there are limited data on surgical outcomes for brain metastases (BMs) that have progressed after prior checkpoint inhibitor treatment. The objective of this study was to identify factors associated with local progression, leptomeningeal disease, and survival for patients undergoing surgical resection of a BM in patients previously treated with checkpoint inhibitor immunotherapy. METHODS: A retrospective, single-center cohort study was conducted with inclusion of adult patients undergoing surgical resection of a BM in the setting of progression after prior checkpoint inhibitor treatment. Univariate and multivariate analyses were performed to identify factors associated with outcomes of interest. RESULTS: Over an 8-year period, 26 patients who underwent resection of 30 BMs met inclusion criteria. Median patient age at surgery was 63.9 years, and median clinical follow-up was 6.9 months (range 0.1 – 52.9). Extracranial disease was present at the time of surgery in 73.3% of cases. There were 6 postoperative complication events (20% of cases) by 30-days. By last follow-up, 65.4% of the cohort had died with a median censored survival of 7.6 months from surgery. Eight patients (30.8%) died within 3 months of surgery. On multivariate analysis, postoperative complications were associated with worse survival (HR 5.33, 95%CI 1.15–24.77, p=0.03). Four BMs had local progression (13.3%), and 60% of procedures were associated with distant progression within a median time of 3.6 months. Leptomeningeal disease developed in 32% of cases. On multivariate analysis, increased time from BM diagnosis to surgery was associated with a greater risk of leptomeningeal disease (OR 1.2, 95%CI 1.00–1.43, p=0.021). CONCLUSION: Patients who require BM resection after prior checkpoint inhibitor treatment have an overall poor prognosis. Although local control rates are acceptable, these patients are at high risk for developing leptomeningeal disease postoperatively. Oxford University Press 2021-08-09 /pmc/articles/PMC8351241/ http://dx.doi.org/10.1093/noajnl/vdab071.104 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Morshed, Ramin
Chung, Jason
Sudhakar, Vivek
Cummins, Daniel
Young, Jacob
Hervey-Jumper, Shawn
Theodosopoulos, Philip
Aghi, Manish
SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series
title SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series
title_full SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series
title_fullStr SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series
title_full_unstemmed SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series
title_short SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series
title_sort surg-11. surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351241/
http://dx.doi.org/10.1093/noajnl/vdab071.104
work_keys_str_mv AT morshedramin surg11surgeryforcontrolofbrainmetastasesafterpriorcheckpointinhibitorimmunotherapyasinglecenterseries
AT chungjason surg11surgeryforcontrolofbrainmetastasesafterpriorcheckpointinhibitorimmunotherapyasinglecenterseries
AT sudhakarvivek surg11surgeryforcontrolofbrainmetastasesafterpriorcheckpointinhibitorimmunotherapyasinglecenterseries
AT cumminsdaniel surg11surgeryforcontrolofbrainmetastasesafterpriorcheckpointinhibitorimmunotherapyasinglecenterseries
AT youngjacob surg11surgeryforcontrolofbrainmetastasesafterpriorcheckpointinhibitorimmunotherapyasinglecenterseries
AT herveyjumpershawn surg11surgeryforcontrolofbrainmetastasesafterpriorcheckpointinhibitorimmunotherapyasinglecenterseries
AT theodosopoulosphilip surg11surgeryforcontrolofbrainmetastasesafterpriorcheckpointinhibitorimmunotherapyasinglecenterseries
AT aghimanish surg11surgeryforcontrolofbrainmetastasesafterpriorcheckpointinhibitorimmunotherapyasinglecenterseries